194 related articles for article (PubMed ID: 12933586)
1. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
2. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
3. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia.
Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ
Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040
[TBL] [Abstract][Full Text] [Related]
4. Murine and math models for the level of stable mixed chimerism to cure beta-thalassemia by nonmyeloablative bone marrow transplantation.
Roberts C; Kean L; Archer D; Balkan C; Hsu LL
Ann N Y Acad Sci; 2005; 1054():423-8. PubMed ID: 16339691
[TBL] [Abstract][Full Text] [Related]
5. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
[TBL] [Abstract][Full Text] [Related]
6. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
7. Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemoglobinopathy.
Hayashi S; Abdulmalik O; Peranteau WH; Ashizuka S; Campagnoli C; Chen Q; Horiuchi K; Asakura T; Flake AW
Exp Hematol; 2003 Feb; 31(2):176-84. PubMed ID: 12591283
[TBL] [Abstract][Full Text] [Related]
8. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
[TBL] [Abstract][Full Text] [Related]
9. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
[TBL] [Abstract][Full Text] [Related]
10. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
Walters MC; Patience M; Leisenring W; Rogers ZR; Aquino VM; Buchanan GR; Roberts IA; Yeager AM; Hsu L; Adamkiewicz T; Kurtzberg J; Vichinsky E; Storer B; Storb R; Sullivan KM;
Biol Blood Marrow Transplant; 2001; 7(12):665-73. PubMed ID: 11787529
[TBL] [Abstract][Full Text] [Related]
11. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions.
Felfly H; Trudel M
Br J Haematol; 2010 Feb; 148(4):646-58. PubMed ID: 19930185
[TBL] [Abstract][Full Text] [Related]
12. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
13. Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants.
Peranteau WH; Hayashi S; Abdulmalik O; Chen Q; Merchant A; Asakura T; Flake AW
Blood; 2015 Sep; 126(10):1245-54. PubMed ID: 26124498
[TBL] [Abstract][Full Text] [Related]
14. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.
Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M
Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695
[TBL] [Abstract][Full Text] [Related]
15. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
18. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia.
Takatu A; Nash RA; Zaucha JM; Little MT; Georges GE; Sale GE; Zellmer E; Kuhr CS; Lothrop CD; Storb R
Biol Blood Marrow Transplant; 2003 Nov; 9(11):674-82. PubMed ID: 14652850
[TBL] [Abstract][Full Text] [Related]
20. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
